Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$15.33 USD
+0.81 (5.54%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $15.33 +0.01 (0.03%) 5:28 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ARQT 15.33 +0.81(5.54%)
Will ARQT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARQT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARQT
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates
ARQT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth
Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for ARQT
Arcutis Biotherapeutics Inc (ARQT) Q2 2025: Everything You Need to Know Ahead of Earnings
Arcutis: Leveraging Zoryve's Success While Positioning For Pipeline Expansion
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Carvana upgraded, Ulta Beauty downgraded: Wall Street's top analyst calls
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday